Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The "CAR T-Cell Therapy for Multiple Myeloma Market - A Global and Regional Analysis: Focus on Product, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.
Multiple myeloma is a rare form of blood cancer that originates in plasma cells, a type of white blood cell responsible for producing antibodies (immunoglobulins) that help the body fight infection. In multiple myeloma, normal plasma cells transform into abnormal, cancerous cells that multiply uncontrollably and produce faulty antibodies known as M proteins. These abnormal proteins and proliferating cells disrupt the production of healthy blood cells, impair immune function, and can cause widespread complications affecting the bones, kidneys, and overall blood cell production. Although multiple myeloma currently has no cure, advances in treatment have significantly improved the ability to manage symptoms, slow disease progression, and enhance quality of life for patients.
The chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment modality, offering new hope for patients with relapsed or refractory multiple myeloma (RRMM). Building upon traditional treatments such as autologous stem cell transplantation and monoclonal antibody therapies, CAR T-cells are engineered to recognize and destroy myeloma cells by targeting specific surface antigens. The recent approval of two CAR T-cell therapies - Abecma and Carvykti - by the FDA has demonstrated promising clinical outcomes, including high response rates and improved survival in heavily pretreated patients. Ongoing clinical trials continue to investigate novel CAR constructs, combination strategies, and earlier-line use to further enhance efficacy and overcome existing limitations such as high costs, manufacturing complexity, and side effect profiles. These developments signal a transformative shift in Multiple myeloma treatment and pave the way for more personalized and effective therapeutic approaches.
The CAR T-Cell Therapy for Multiple Myeloma market is primarily driven by the high efficacy of BCMA-targeted therapies such as Abecma and Carvykti, which have demonstrated deep, durable responses in relapsed or refractory cases, significantly outperforming traditional treatment options. Additionally, the rising global incidence of multiple myeloma, particularly among aging populations, is increasing the demand for advanced, personalized treatment approaches. Regulatory agencies like the FDA and EMA are further propelling market growth by granting fast-track approvals and priority designations to CAR T therapies, recognizing their transformative potential. Moreover, substantial investments from pharmaceutical giants and biotech firms in manufacturing capabilities, research and development, and clinical infrastructure are accelerating the commercialization and accessibility of CAR T-cell therapies worldwide.
Despite its therapeutic promise, the CAR T-Cell Therapy for Multiple Myeloma market faces several significant challenges. One of the most pressing issues is the high cost of treatment, often exceeding USD 400,000 per patient, which poses substantial reimbursement hurdles and limits affordability - particularly in low- and middle-income countries. The complex and individualized manufacturing process further adds to the burden, creating supply chain bottlenecks and scalability issues that hinder widespread adoption. Additionally, CAR T-cell therapies are associated with severe side effects such as cytokine release syndrome (CRS) and neurotoxicity, necessitating intensive care and restricting use to highly specialized treatment centres. In many developing regions, limited healthcare infrastructure, a shortage of trained personnel, and low awareness further constrain market expansion and equitable access.
The competitive landscape of the global CAR T-Cell Therapy for Multiple Myeloma market is rapidly advancing, fuelled by increasing demand for precision oncology treatments and breakthroughs in cell and gene therapy. The market, once limited to conventional therapies such as immunomodulatory drugs and proteasome inhibitors, is now witnessing a surge in innovation with the approval and commercialization of BCMA-targeted CAR T-cell products like Abecma and Carvykti. Leading biopharmaceutical companies, including Bristol-Myers Squibb, Johnson & Johnson (Legend Biotech), Novartis, and Gilead Sciences, are actively expanding their pipelines and scaling manufacturing capabilities to meet rising global demand. Additionally, emerging biotech firms and academic spin-offs are entering the space with next-generation and allogeneic CAR T constructs, further intensifying competition. The growing number of strategic partnerships, licensing agreements, and M&A activities reflects a dynamic market environment focused on improving access, reducing production timelines, and enhancing therapeutic durability. As regulatory bodies worldwide offer accelerated pathways and supportive frameworks, the market is poised for robust expansion, especially as CAR T-cell therapies move into earlier lines of treatment and explore novel antigen targets beyond BCMA.
The CAR T-Cell Therapy for Multiple Myeloma market holds substantial growth potential, particularly through expansion in emerging markets such as India, China, and Latin America. Improvements in clinical infrastructure and local regulatory approvals - like NexCAR19 in India - are paving the way for greater access in cost-sensitive regions. Additionally, there is increasing momentum in diversifying the therapeutic pipeline beyond BCMA, with new targets like GPRC5D and FcRH5 offering treatment options for patients who relapse after BCMA-based therapies. Advancements in manufacturing technologies, including automation, closed-loop systems, and point-of-care platforms, promise to enhance scalability and reduce turnaround times. Furthermore, integrating CAR T-cell therapy with combination treatments - such as checkpoint inhibitors or monoclonal antibodies - presents a promising strategy to extend response durability and reduce the risk of relapse, thereby broadening the clinical utility of these therapies.
Company Profiles
- 5.2.1 Bristol-Myers Squibb Company
- 5.2.2 Novartis AG
- 5.2.3 Johnson & Johnson (Legend Biotech)
- 5.2.4 Gilead Sciences
- 5.2.5 Others
For more information about this report visit https://www.researchandmarkets.com/r/uboior
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
